Neuropsychiatric Disease and Treatment (2018-06-01)

COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

  • Kaneko H,
  • Miura I,
  • Kanno-Nozaki K,
  • Horikoshi S,
  • Hino M,
  • Yabe H

Journal volume & issue
Vol. Volume 14
pp. 1657 – 1663


Read online

Haruka Kaneko,1,2 Itaru Miura,1 Keiko Kanno-Nozaki,1 Sho Horikoshi,1 Mizuki Hino,1 Hirooki Yabe1 1Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan; 2Department of Neuropsychiatry, Hoshi General Hospital, Fukushima, Japan Introduction: The COMT Val 108/158 Met polymorphism (rs4680) may affect treatment response to antipsychotics, as well as metabolism and dynamics of neurotransmitters during the treatment of schizophrenia. We investigated the effects of the COMT Val 108/158 Met polymorphism on treatment response to aripiprazole and plasma monoamine metabolite levels in patients with acute schizophrenia. Materials and methods: Forty patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured Positive and Negative Syndrome Scale (PANSS) and plasma levels of homovanillic acid (HVA) and plasma MHPG (3-methoxy-4-hydroxyphenethyleneglycol) at baseline and endpoint. The COMT Val 108/158 Met polymorphism was genotyped with the polymerase chain reaction and restriction fragment length polymorphism. Results: There were significant genotype–time interactions on PANSS total and general psychopathology scores, with Met/Met genotype showing greater improvement. The response rate to aripiprazole did not differ between COMT Val 108/158 Met genotype groups. We found a significant time effect on plasma MHPG levels, but no time effect on plasma HVA levels or time–genotype interactions in the plasma levels of HVA and MHPG. Although the responder rate did not differ among the 3 genotype groups. Conclusion: Our results suggest that individuals with the Met/Met genotype had greater improvement in PANSS score after the treatment with aripiprazole. On the other hand, the Val 108/158 Met polymorphism may not induce changes in plasma levels of monoamine metabolites during aripiprazole treatment. Because of the small sample size, further studies are needed to confirm and to extend our results. Keywords: schizophrenia, COMT, Val 108/158 Met polymorphism (rs4680), aripiprazole, pharmacogenetics